Cargando…

Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker

OBJECTIVE: Blood tests to monitor disease activity, attack severity, or treatment impact in neuromyelitis optica spectrum disorder (NMOSD) have not been developed. This study investigated the relationship between serum glial fibrillary acidic protein (sGFAP) concentration and NMOSD activity and asse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aktas, Orhan, Smith, Michael A., Rees, William A., Bennett, Jeffrey L., She, Dewei, Katz, Eliezer, Cree, Bruce A. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252046/ https://www.ncbi.nlm.nih.gov/pubmed/33724534 http://dx.doi.org/10.1002/ana.26067

Ejemplares similares

The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis
por: Storoni, Mithu, et al.
Publicado: (2011)

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
por: Aktas, Orhan, et al.
Publicado: (2023)

Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum
por: Weinshenker, Brian G, et al.
Publicado: (2023)

Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders
por: Kim, Hyunjin, et al.
Publicado: (2022)

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder
por: Marignier, Romain, et al.
Publicado: (2021)

Pharmacodynamic modelling and exposure–response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders
por: Yan, Li, et al.
Publicado: (2022)

Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein
por: Hyun, Jae-Won, et al.
Publicado: (2021)

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
por: Cree, Bruce AC, et al.
Publicado: (2015)

Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder
por: Zhang, Tian-Xiang, et al.
Publicado: (2021)

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial
por: Bennett, Jeffrey L., et al.
Publicado: (2022)

Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis
por: Yan, Li, et al.
Publicado: (2021)

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial
por: Rensel, Mary, et al.
Publicado: (2021)

The Gut Microbiome in Neuromyelitis Optica
por: Zamvil, Scott S., et al.
Publicado: (2017)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023)

Neuromyelitis optica spectrum disorder: Patient experience and quality of life
por: Beekman, Janine, et al.
Publicado: (2019)

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
por: Fujihara, Kazuo, et al.
Publicado: (2020)

Spectrum of sublytic astrocytopathy in neuromyelitis optica
por: Guo, Yong, et al.
Publicado: (2021)

Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
por: Krumbholz, Markus, et al.
Publicado: (2015)

Neuromyelitis optica spectrum disorders: An update
por: Pandit, Lekha
Publicado: (2015)

Treatment of Neuromyelitis Optica Spectrum Disorders
por: Chan, Koon-Ho, et al.
Publicado: (2021)

Satralizumab for neuromyelitis optica spectrum disorder
Publicado: (2021)

Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders
por: Fan, Xueli, et al.
Publicado: (2016)

Update on biomarkers in neuromyelitis optica
por: Melamed, Esther, et al.
Publicado: (2015)

Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis
por: Metz, Imke, et al.
Publicado: (2016)

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
por: Stellmann, Jan-Patrick, et al.
Publicado: (2017)

Late Onset of Neuromyelitis Optica Spectrum Disorders
por: Fragoso, Yara Dadalti, et al.
Publicado: (2019)

Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica
por: Paul, Friedemann, et al.
Publicado: (2007)

Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience
por: Jagtap, Sujit Abajirao, et al.
Publicado: (2015)

Association of cigarette smoking with neuromyelitis optica-immunoglobulin G sero-positivity in neuromyelitis optica spectrum disorder
por: Eskandarieh, Sharareh, et al.
Publicado: (2019)

The Calm Between Storms: Serum Biomarkers in Assessing Interattack Astrocytopathy in Neuromyelitis Optica Spectrum Disorder
por: Goldschmidt, Carolyn, et al.
Publicado: (2021)

Clinical utility of serum glial fibrillary acidic protein in glial neoplasm
por: Yadav, Nidhi, et al.
Publicado: (2022)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022)

Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes
por: Lana-Peixoto, Marco A., et al.
Publicado: (2019)

Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder
por: Kim, Woojun, et al.
Publicado: (2012)

Sleep abnormality in neuromyelitis optica spectrum disorder
por: Song, Yijun, et al.
Publicado: (2015)

Three cases of neuromyelitis optica spectrum disorder
por: Matsusue, Eiji, et al.
Publicado: (2016)

Neuromyelitis Optica Spectrum Disorder Presenting with Pseudoathetosis
por: Seok, Hung Youl, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rj76758bej5jds5t5ke0r8jsa6